Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016

Watchlist Manager
Shanghai MicroPort Endovascular MedTech Group Co Ltd Logo
Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
Watchlist
Price: 105.26 CNY -3.02% Market Closed
Market Cap: 13B CNY
Have any thoughts about
Shanghai MicroPort Endovascular MedTech Group Co Ltd?
Write Note

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai MicroPort Endovascular MedTech Group Co Ltd
SSE:688016
Cash from Operating Activities
ÂĄ558.3m
CAGR 3-Years
37%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Cash from Operating Activities
ÂĄ2.7B
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
Cash from Operating Activities
ÂĄ212.6m
CAGR 3-Years
20%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Autobio Diagnostics Co Ltd
SSE:603658
Cash from Operating Activities
ÂĄ1.5B
CAGR 3-Years
-3%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
Cash from Operating Activities
ÂĄ1.1B
CAGR 3-Years
-39%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Cash from Operating Activities
ÂĄ1.4B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicroPort Endovascular MedTech Group Co Ltd
Glance View

Market Cap
13B CNY
Industry
Health Care

Shanghai MicroPort Endovascular MedTech Group Co Ltd stands as a testament to China's burgeoning capabilities in the medtech landscape. The company was born from a vision to develop innovative solutions for treating cardiovascular diseases, which are among the leading causes of mortality worldwide. MicroPort Endovascular crafts specialized medical devices aimed at minimally invasive therapies, particularly in the vascular intervention domain. They produce stents, embolization coils, and vascular grafts—tools essential for intricate procedures like repairing damaged blood vessels or preventing life-threatening aneurysms. By aligning with cutting-edge technological advancements and rigorous clinical testing, MicroPort Endovascular has cemented its reputation as a trusted partner for medical professionals seeking reliable, effective, and technologically advanced instruments. MicroPort Endovascular’s revenue model is intrinsically linked to the global demand for cardiovascular solutions. With increasing incidences of cardiovascular diseases, partly due to lifestyle shifts and an aging population, the firm strategically positions itself in both domestic and international markets to capitalize on this demand. Their business operations span research and development, manufacturing, and distribution, allowing them to maintain control over quality and innovation while optimizing costs. Revenue flows from direct sales to hospitals and healthcare providers, as well as partnerships with distributors, ensuring widespread market penetration. Their continuous investment in R&D not only drives the introduction of new products but also enhances existing ones, thereby maintaining a competitive edge in a field where innovation is tantamount to success.

Intrinsic Value
176.77 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
558.3m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicroPort Endovascular MedTech Group Co Ltd's Cash from Operating Activities amounts to 558.3m CNY.

What is Shanghai MicroPort Endovascular MedTech Group Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
39%

Over the last year, the Cash from Operating Activities growth was 67%. The average annual Cash from Operating Activities growth rates for Shanghai MicroPort Endovascular MedTech Group Co Ltd have been 37% over the past three years , 39% over the past five years .

Back to Top